Investigational Drug Information for CRLX101
✉ Email this page to a colleague
What is the drug development status for CRLX101?
CRLX101 is an investigational drug.
There have been 12 clinical trials for CRLX101.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Cerulean Pharma Inc., NewLink Genetics Corporation, and National Cancer Institute (NCI).
Summary for CRLX101
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 134 |
| WIPO Patent Applications | 80 |
| Japanese Patent Applications | 72 |
| Clinical Trial Progress | Phase 2 (2014-07-01) |
| Vendors | 20 |
Recent Clinical Trials for CRLX101
| Title | Sponsor | Phase |
|---|---|---|
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | National Cancer Institute (NCI) | Phase 2 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | Cerulean Pharma Inc. | Phase 1 |
Clinical Trial Summary for CRLX101
Top disease conditions for CRLX101
Top clinical trial sponsors for CRLX101
US Patents for CRLX101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
